Sebastien Bonnet

Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing.

Upregulation of L-type Ca2+ channels in mesenteric and skeletal arteries of SHR.

Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.

Role of Ca(2+)-sensitive K(+) channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases.

Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats.

Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells.

Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats.

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.

Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes.

Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase.

A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system.

An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension.

Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury.

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension.

The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.

Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.

CD36 expression contributes to age-induced cardiomyopathy in mice.

Air pollutant emissions from rice straw open field burning in India, Thailand and the Philippines.

Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats.

Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis.

Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.

HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism.

Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension.

Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases.

Role for miR-204 in human pulmonary arterial hypertension.

Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension.

RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.

The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension.

From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.

Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.

Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.

Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension.

Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH.

Framework for life cycle sustainability assessment of municipal solid waste management systems with an application to a case study in Thailand.

Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension.

Ozone and its potential control strategy for Chon Buri city, Thailand.

The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.

Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.

Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension.

Pim-1: A new biomarker in pulmonary arterial hypertension.

Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension.

Targeting cell motility in pulmonary arterial hypertension.

Signal transduction in the development of pulmonary arterial hypertension.

STAT3 signaling in pulmonary arterial hypertension.

Anti-inflammatory and immunosuppressive agents in PAH.

Role for DNA damage signaling in pulmonary arterial hypertension.

Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review.

miRNAs in PAH: biomarker, therapeutic target or both?

Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension.

Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series).

Alternatives to the six-minute walk test in pulmonary arterial hypertension.

Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.

A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension.

Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension.

Adaptation and Remodelling of the Pulmonary Circulation in Pulmonary Hypertension.

NOGGIN: a new therapeutic target for PH? Focus on "Noggin Inhibits Hypoxia-Induced Proliferation by Targeting Store-operated Calcium Entry and TRPC Channels".